Zhenhai Lu

Sun Yat-sen University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Zhizhong Pan

Sun Yat-sen University

Jianhong Peng

Sun Yat-sen University

Desen Wan

State Key Laboratory of Oncology in South China

Rongxin Zhang

Guangdong Pharmaceutical University

Xiaojun Wu

Sun Yat-sen University Cancer Center

Junzhong Lin

Sun Yat-sen University

Peirong Ding

Sun Yat-sen University

Li Li

Sun Yat-sen University Cancer Center

Yujing Fang

Sun Yat-sen University

Fulong Wang

University of New Mexico

Cooperative Institutions

Sun Yat-sen University

205

Sun Yat-sen University Cancer Center

170

State Key Laboratory of Oncology in South China

129

Key Laboratory of Guangdong Province

Chinese Academy of Medical Sciences & Peking Union Medical College

The First Affiliated Hospital, Sun Yat-sen University

Peking University

Sichuan University

University of Colorado Denver

Chinese Academy of Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Table S4 from Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair

Xue-Cen Wang Xin Yue Rongxin Zhang Tingyu Liu Zhizhong Pan

<p>Supplementary Table S4 shows the correlation of clinicopathological parameters and RFC4 expression.</p>

Radioresistance

Non-homologous end joining

DNA Damage Repair

10.1158/1078-0432.22472001.v1

Cite

Citations (0)

Short-Term Results of the SONCAR Study: Optimized Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients - A Prospective Randomized Controlled Phase III Study

Rongxin Zhang Fulong Wang Xinhua Jiang Hao Wang Zhifan Zeng

Chemoradiotherapy

10.2139/ssrn.4596447

Cite

Citations (0)

Hepatitis B Virus Infection Predicts Better Survival In Patients With Colorectal Liver-only Metastases Undergoing Liver Resection

Journal of Cancer (2018)

Yujie Zhao Junzhong Lin Jianhong Peng Yuxiang Deng Ruixia Zhao

Objective: Hepatitis B virus (HBV) infection has been shown to decrease the risk of liver metastasis in patients with non-metastatic colorectal cancer (CRC). However, the prognostic value of HBV infection in long-term survival of patients with colorectal liver-only metastases (CRLM) after liver resection has not yet been evaluated. This study aims to explore the association between HBV infection and survival in CRLM patients. Methods: A total of 289 CRLM patients undergoing liver resection were recruited at our center from September 1999 to August 2015. Patients were divided into an HBV infection group and a non-HBV infection group. Progression-free survival (PFS) and overall survival (OS) related to HBV infection were analyzed using both Kaplan-Meier and multivariate Cox regression methods. Results: HBV infection was found in 12.1 %(35/289) of patients. Of these patients, 31.4 %(11/35) had chronic hepatitis B (CHB), 42.9 % (15/35) were inactive hepatitis B surface antigen (HBsAg) carriers (IC) and 25.7 % (9/35) did not undergo HBV DNA detection. HBV infection was associated with more liver metastases (P = 0.025) and larger-sized liver metastases (P = 0.049). The 3-year OS and PFS rates in the HBV infection group were higher than those in the HBV non-infected group (OS: 75.0 % vs 64.8 %, P = 0.031; PFS: 55.9 % vs 39.6 %, P = 0.034). In multivariate Cox analysis, HBV infection was identified as an independent factor for better 3-year OS (hazard ratio (HR), 0.446; 95 %confidence interval (CI), 0.206-0.966; P = 0.041) but not an independent factor for 3-year PFS. Conclusions: HBV-infected CRLM patients survived longer than non-infected patients. In clinical work, therapeutic regimens and follow-up for HBsAg-positive patients may be different from that for HBsAg-negative patients, even though objective prospective studies are still needed.

Hepatitis B

HBeAg

10.7150/jca.24544

Cite

Citations (11)

Expression and Biological Significance of Leptin, Leptin Receptor, VEGF, and CD34 in Colorectal Carcinoma

Cell Biochemistry and Biophysics (2010)

Liu Hui Desen Wan Pan Zhizhong Cao Lijing Xiaojun Wu

10.1007/s12013-010-9145-5

Cite

Citations (39)

Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial

Cancer Cell (2024)

Weiwei Xiao Gong Chen Yuanhong Gao Junzhong Lin Xiaojun Wu

Clinical endpoint

Chemoradiotherapy

10.1016/j.ccell.2024.07.004

Cite

Citations (7)

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer

Aging (2018)

Jianhong Peng Qingjian Ou Zhizhong Pan Rongxin Zhang Yujie Zhao

Since early diagnosis is very important for treating CRC, we decided to detect peripheral serum canopy fibroblast growth factor signaling regulator 2 (CNPY2) isoform 2 to verify its diagnostic value for CRC patients. Serum samples were collected from 430 CRC patients and 201 healthy controls. Enzyme-linked immunosorbent assay (ELISA) detection kits for CNPY2 isoform 2 were generated and then applied to measure serum CNPY2 isoform 2 concentrations. Serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were also measured. The median serum CNPY2 isoform 2 concentrations in all CRC patients were significantly higher than those in the healthy control group (all P<0.001). Those with stage I CRC presented the highest area under the receiver operating characteristic curve (AUC) for CNPY2 isoform 2 [0.707, 95% confidence interval (CI): 0.649-0.765, P<0.001]. The diagnostic efficiency of the combination of CNPY2 isoform 2, CEA and CA19-9 was significantly higher than that of each biomarker detected separately (all P<0.0167). Serum CNPY2 isoform 2 may be a valuable biomarker for the early detection of CRC and presents an improvement in the diagnostic efficiency by combination of CEA and CA19-9.

Carcinoembryonic antigen

10.18632/aging.101512

Cite

Citations (9)

Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway

Cancer Letters (2015)

Nan Shao Zhenhai Lu Yunjian Zhang Mian Wang Wen Li

Estrogen receptor alpha

10.1016/j.canlet.2015.05.009

Cite

Citations (65)

Serum biomarkers REG1A and REG3A combined with the traditional CEA represent a novel nomogram for the screening and risk stratification of colorectal cancer

Clinical & Translational Oncology (2024)

Long Yu Hao Wang Fulong Wang Jian Guo Binyi Xiao

Nomogram

Lasso

10.1007/s12094-024-03566-6

Cite

Citations (0)

Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery

Tumor Biology (2017)

Jianhong Peng Junzhong Lin Miao‐Zhen Qiu Yujie Zhao Yuxiang Deng

Tumor response to preoperative chemoradiotherapy and postoperative survival differs among patients with locally advanced rectal cancer. The objective was to find correlations of mutated oncogenes and clinical outcomes in locally advanced rectal cancer. A total of 70 patients with preoperative preoperative chemoradiotherapy followed by radical surgery at a single cancer center between 2006 and 2012 were enrolled. Pretreatment tumor biopsy samples were assayed for 238 mutation hotspots harboring 19 oncogenes by time-of-flight mass spectrometry and OncoCarta Array. Oncogene mutations were found in 48.6% of patients (34/70). KRAS was the most frequent driver mutation, found in 35.7% of patients (25/70), followed by PIK3CA (14.3%), NRAS (5.7%), FLT3 (2.9%), and BRAF (1.4%). Multiple gene mutations were observed in eight patients (11.4%). Tumors with KRAS mutations responded poorly to preoperative chemoradiotherapy (p = 0.044). Patients with oncogene mutations had worse 3-year disease-free survival than those without mutations (67.2% vs 94.2%, p = 0.010). Patients with KRAS or RAS mutations had lower 3-year disease-free survival (68% vs 88.3%, p = 0.016; 65.5% vs 92.3%, p = 0.004, respectively) and 3-year overall survival (88% vs 95.4%, p = 0.020; 89.7% vs 94.9%, p = 0.036, respectively) than those without KRAS or RAS mutations. Oncogene mutation status affected tumor response to treatment and long-term survival in locally advanced rectal cancer.

Chemoradiotherapy

Radical surgery

10.1177/1010428317709638

Cite

Citations (20)

Supplementary Table S4 from Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair

Xue-Cen Wang Xin Yue Rongxin Zhang Tingyu Liu Zhizhong Pan

<p>Supplementary Table S4 shows the correlation of clinicopathological parameters and RFC4 expression.</p>

Radioresistance

Non-homologous end joining

10.1158/1078-0432.22472001

Cite

Citations (0)